Is Pediatrix Medical Group, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Pediatrix Medical Group, Inc. has moved from attractive to very attractive, indicating a positive shift in its perceived value. Based on the current metrics, the company appears to be undervalued. Key ratios include a P/E ratio of 8, an EV to EBITDA of 7.17, and a PEG ratio of 0.19, all of which suggest that the stock is trading at a discount compared to its earnings growth potential.
In comparison to peers, Pediatrix Medical Group has a lower P/E ratio than Hims & Hers Health, Inc., which stands at 54.76, and a more favorable EV to EBITDA ratio than RadNet, Inc., which is at 26.07. This further reinforces the notion that Pediatrix is undervalued relative to its industry peers. Additionally, the company's stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 25.38% compared to the S&P 500's 13.30%, highlighting its strong performance in the market.